FDA QiDP designation is a significant milestone PARK CITY, UTAH, UNITED STATES, July 31, 2023/EINPresswire.com/ — Kinnear Pharmaceuticals, LLC, a subsidiary of N8 Medical, Inc. today announced the U.S. Food
Author: Olga Yanovskaya
New Publication regarding Ceragenin CSA-131’s Potent Efficacy against fungal pathogen Candida auris, a New Serious Global Health Threat
Colistin is the last agent used to combat bacteria that are resistant to the strongest antibiotics. Colistin has remained the best tool available to treat multidrug resistant bacteria because bacteria
A recent published study by Professor Jordi Vila and his colleagues at the University of Barcelona, Spain has found that CSA-131 is highly effective against Colistin resistant strains of Pseudomonas